<![CDATA[How KRAS G12C Data Should Shape Combination Trial Design]]>

Data ReadoutpositivePositive

AI Analysis

Summary

Dr. David Gandara discusses how EMPOWER-Lung 1 trial findings in KRAS G12C-mutated disease should inform the design of future combination trials. The article focuses on clinical trial design implications rather than presenting specific trial results or regulatory decisions.

Clinical Trial Data

Outcome Details

EMPOWER-Lung 1 findings in KRAS G12C-mutated disease discussed for informing combination trial design

Importance:4/10

Sentiment:

0.50

KRAS G12CEMPOWER-Lung 1combination therapylung cancerclinical trial design

Read the original article

Published by Cancer Network on September 24, 2026 2:00 PM

Read Original